New horizons for targeted treatment of neuroendocrine tumors

Alberto Mangano, Georgios D. Lianos, Dimitrios H. Roukos, Sam E. Mason, Hoon Yub Kim, Gianlorenzo Dionigi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.

Original languageEnglish
Pages (from-to)1059-1065
Number of pages7
JournalFuture Oncology
Volume12
Issue number8
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Neuroendocrine Tumors
Randomized Controlled Trials
Therapeutics
Growth Factor Receptors
Angiogenesis Inducing Agents
Somatostatin
Protein-Tyrosine Kinases
Disease-Free Survival
Hormones
Neoplasms

Keywords

  • carcinoid tumors
  • gastroenteropancreatic tumors
  • intertumor heterogeneity
  • intratumor heterogeneity
  • neuroendocrine tumors
  • targeted agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mangano, A., Lianos, G. D., Roukos, D. H., Mason, S. E., Kim, H. Y., & Dionigi, G. (2016). New horizons for targeted treatment of neuroendocrine tumors. Future Oncology, 12(8), 1059-1065. https://doi.org/10.2217/fon.16.8

New horizons for targeted treatment of neuroendocrine tumors. / Mangano, Alberto; Lianos, Georgios D.; Roukos, Dimitrios H.; Mason, Sam E.; Kim, Hoon Yub; Dionigi, Gianlorenzo.

In: Future Oncology, Vol. 12, No. 8, 01.04.2016, p. 1059-1065.

Research output: Contribution to journalReview article

Mangano, A, Lianos, GD, Roukos, DH, Mason, SE, Kim, HY & Dionigi, G 2016, 'New horizons for targeted treatment of neuroendocrine tumors', Future Oncology, vol. 12, no. 8, pp. 1059-1065. https://doi.org/10.2217/fon.16.8
Mangano A, Lianos GD, Roukos DH, Mason SE, Kim HY, Dionigi G. New horizons for targeted treatment of neuroendocrine tumors. Future Oncology. 2016 Apr 1;12(8):1059-1065. https://doi.org/10.2217/fon.16.8
Mangano, Alberto ; Lianos, Georgios D. ; Roukos, Dimitrios H. ; Mason, Sam E. ; Kim, Hoon Yub ; Dionigi, Gianlorenzo. / New horizons for targeted treatment of neuroendocrine tumors. In: Future Oncology. 2016 ; Vol. 12, No. 8. pp. 1059-1065.
@article{61b3c3ff9c3043b392204d8720a6ce91,
title = "New horizons for targeted treatment of neuroendocrine tumors",
abstract = "Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.",
keywords = "carcinoid tumors, gastroenteropancreatic tumors, intertumor heterogeneity, intratumor heterogeneity, neuroendocrine tumors, targeted agents",
author = "Alberto Mangano and Lianos, {Georgios D.} and Roukos, {Dimitrios H.} and Mason, {Sam E.} and Kim, {Hoon Yub} and Gianlorenzo Dionigi",
year = "2016",
month = "4",
day = "1",
doi = "10.2217/fon.16.8",
language = "English",
volume = "12",
pages = "1059--1065",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - New horizons for targeted treatment of neuroendocrine tumors

AU - Mangano, Alberto

AU - Lianos, Georgios D.

AU - Roukos, Dimitrios H.

AU - Mason, Sam E.

AU - Kim, Hoon Yub

AU - Dionigi, Gianlorenzo

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.

AB - Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.

KW - carcinoid tumors

KW - gastroenteropancreatic tumors

KW - intertumor heterogeneity

KW - intratumor heterogeneity

KW - neuroendocrine tumors

KW - targeted agents

UR - http://www.scopus.com/inward/record.url?scp=84961864423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961864423&partnerID=8YFLogxK

U2 - 10.2217/fon.16.8

DO - 10.2217/fon.16.8

M3 - Review article

VL - 12

SP - 1059

EP - 1065

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 8

ER -